Roche Q1 Sales Fall Short on Weak Avastin Demand

ZURICH, April 14 (Reuters) - Demand for Roche's (ROG.VX) key cancer drug Avastin fell further in the first quarter, adding to the Swiss drugmaker's woes as it grapples with a slump in Tamiflu revenue and a push by governments to cut health costs.